India releases list of drugs approved without local trials
This article was originally published in Scrip
Faced with a barrage of questions and allegations of regulatory lapses in approving drugs for launch in the country, India's drugs regulator appears to have launched a transparency drive, putting out a host of approval details in public domain that includes a list of drugs recommended for approval without trials in the country.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.